Bank Pictet & Cie Europe AG Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bank Pictet & Cie Europe AG lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 27.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,827 shares of the biotechnology company’s stock after buying an additional 613 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Sarepta Therapeutics were worth $353,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Capital International Investors grew its holdings in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after purchasing an additional 76,032 shares during the last quarter. Farallon Capital Management LLC grew its stake in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Sarepta Therapeutics by 6.3% during the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Sarepta Therapeutics by 26.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock valued at $75,040,000 after buying an additional 120,535 shares during the last quarter. Finally, Fiera Capital Corp lifted its stake in Sarepta Therapeutics by 4.3% in the second quarter. Fiera Capital Corp now owns 382,645 shares of the biotechnology company’s stock valued at $60,458,000 after buying an additional 15,606 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Up 0.9 %

Shares of Sarepta Therapeutics stock opened at $128.42 on Wednesday. The company has a 50-day moving average of $128.87 and a two-hundred day moving average of $132.42. The stock has a market cap of $12.14 billion, a PE ratio of 1,167.45 and a beta of 0.82. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business posted ($0.27) EPS. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SRPT. Royal Bank of Canada restated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 14th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday. They set a “buy” rating and a $165.00 price target on the stock. Finally, Barclays reduced their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.